<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2015-8-111-122</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИКА И ФАРМАКОТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR THE PRACTITIONER</subject></subj-group></article-categories><title-group><article-title>РАНДОМИЗИРОВАННОЕ СРАВНЕНИЕ ДВУХ ПОДХОДОВ К ДОЗИРОВАНИЮ ВАРФАРИНА В УСЛОВИЯХ КАРДИОЛОГИЧЕСКОГО СТАЦИОНАРА</article-title><trans-title-group xml:lang="en"><trans-title>RANDOMIZED COMPARISON OF TWO APPROACHES TO WARFARIN DOSAGE IN CARDIOVASCULAR HOSPITAL SECTION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мищенко</surname><given-names>Л. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mishchenko</surname><given-names>L. N.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аверков</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Averkov</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гордеев</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Gordeev</surname><given-names>I. G.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тюлькина</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyulkina</surname><given-names>E. E.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павликова</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlikova</surname><given-names>E. P.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левчук</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Levchuk</surname><given-names>N. N.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плетникова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Pletnikova</surname><given-names>I. G.</given-names></name></name-alternatives><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова, г. Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian National Research Medical University named after N.I. Pirogov, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Россйский университет дружбы народов, Москва; &#13;
Городская клиническая больница №15 имени О. М. Филатова, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples’ Friendship University of Russia, Moscow; &#13;
CCH №15 named after O. M. Filatov, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Городская клиническая больница №15 имени О. М. Филатова, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>CCH №15 named after O. M. Filatov, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>28</day><month>08</month><year>2015</year></pub-date><volume>0</volume><issue>8</issue><fpage>111</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мищенко Л.Н., Аверков О.В., Гордеев И.Г., Тюлькина Е.Е., Павликова Е.П., Левчук Н.Н., Плетникова И.Г., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Мищенко Л.Н., Аверков О.В., Гордеев И.Г., Тюлькина Е.Е., Павликова Е.П., Левчук Н.Н., Плетникова И.Г.</copyright-holder><copyright-holder xml:lang="en">Mishchenko L.N., Averkov O.V., Gordeev I.G., Tyulkina E.E., Pavlikova E.P., Levchuk N.N., Pletnikova I.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/183">https://russjcardiol.elpub.ru/jour/article/view/183</self-uri><abstract><sec><title> </title><p> </p></sec><sec><title>Цель</title><p>Цель. Сравнение двух подходов к дозированию варфарина: стандартного и с использованием клинического алгоритма.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В качестве изучаемого подхода к дозированию варфарина использовалась методика, учитывающая клинические особенности больных.  В группу изучаемого подхода (группу вмешательства) рандомизирован 31 человек, в группу с использованием стандартного подхода (группу контроля) — 29 человек с различными показаниями к лечению антагонистом витамина  К. Целевой диапазон международного нормализиванного отношения (МНО) для всех больных составлял от 2,0 до 3,0.</p></sec><sec><title>Результаты</title><p>Результаты. Стабильного целевого МНО в обеих группах в период госпитализации  удалось добиться лишь у небольшой части больных: 19,4% в группе вмешательства и 17,2% в группе контроля. Больные группы вмешательства достигали стабильного МНО в среднем к 6,8 дню, что почти в два раза быстрее больных группы контроля, которые достигали первого из последовательных целевых МНО в среднем к 12,4 дню (p&lt;0,05). Доля значений МНО выше 4,0 в группе вмешательства составила 3,6%, в группе контроля — 18,2% (p&lt;0,05). Тромбоэмболических событий (инсультов, рецидивов тромбоэмболии ветвей лёгочной артерии) не было в обеих группах. В каждой группе было зарегистри - ровано по одному эпизоду кровотечения.</p></sec><sec><title>Заключение</title><p>Заключение. Возможности по достижению целевого МНО, независимо от режима дозирования, в условиях стационара очень ограничены. У больных, достигших стабильного МНО в целевом диапазоне, использование клинического алгоритма для подбора дозы варфарина, позволило добиться этих значений  значительно раньше, чем при использовании стандартного подхода. Частота развития избыточной гипокоагуляции при использовании клинического алгоритма меньше таковой в группе стандартного дозирования.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To compare two approaches to warfarin dosage formulation: the standard and with the clinical algorithm.</p></sec><sec><title>Material and methods</title><p>Material and methods. As an approach to warfarin dosage, we have used the method that included clinical properties of the patients. Into the group of the studied approach (intervention group), we randomized 31 person, into the standard approach group (controls) — 29 persons with a variety of indications for vitamin K antagonists treatment. Target diapason of International Normalized Ratio (INR) for all the patients was 2,0 to 3,0.</p></sec><sec><title>Results</title><p>Results. A stable target INR in both groups was reached during hospitalization just in a small part of the patients: 19,4% in intervention group and 17,2% in controls. The patients from intervention group reached stable INR by 6,8 days in average, that is almost two times faster than controls, who had their target INR by 12,4 day in average (p&lt;0,05). Part of the INR values higher than 4,0 in intervention group was 3,6%, in control group — 18,2% (p&lt;0,05). Thromboembolic events (strokes, pulmonary embolism repeats) has not developed in both groups. There was one bleeding episode in each of the groups.</p></sec><sec><title>Conclusion</title><p>Conclusion. Opportunities for targeting INR, not dependent on dosing regimen, are quite restricted in inpatient settings. The patients having reached target INR, usage of clinical algorithm of warfarin dosage helped to achieve these values much faster than in standard approach. Prevalence of excessive hypocoagulation while using the algorithm was lesser than in standard group.</p></sec><sec><title> </title><p> </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>варфарин</kwd><kwd>подбор дозы варфарина</kwd><kwd>МНО</kwd><kwd>стабильное МНО</kwd><kwd>клинический алгоритм</kwd><kwd>стандартный подход</kwd><kwd>гипокоагуляция</kwd><kwd>новые антикоагулянты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>warfarin</kwd><kwd>warfain dose selection</kwd><kwd>INR</kwd><kwd>stable INR</kwd><kwd>clinical algorithm</kwd><kwd>standard approach</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Poller L. International Normalized Ratios (INR): the first 20 years. Thromb Haemost, 2004 Jun, 2 (6): 849-60.</mixed-citation><mixed-citation xml:lang="en">Poller L. International Normalized Ratios (INR): the first 20 years. Thromb Haemost, 2004 Jun, 2 (6): 849-60.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kirkwood TB. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost, 1983 Jun 28, 49 (3): 238-44.</mixed-citation><mixed-citation xml:lang="en">Kirkwood TB. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost, 1983 Jun 28, 49 (3): 238-44.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kimmel SE, French B, Kasner SE, et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 2013 Dec 12, 369 (24): 2283-93.</mixed-citation><mixed-citation xml:lang="en">Kimmel SE, French B, Kasner SE, et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 2013 Dec 12, 369 (24): 2283-93.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Гланц C. Медико-биологическая статистика. Практика, Москва, 1999.</mixed-citation><mixed-citation xml:lang="en">Гланц C. Медико-биологическая статистика. Практика, Москва, 1999.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther, 2008; 84 (3): 326-31.</mixed-citation><mixed-citation xml:lang="en">Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther, 2008; 84 (3): 326-31.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med, 2009; 360 (8): 753-64.</mixed-citation><mixed-citation xml:lang="en">Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med, 2009; 360 (8): 753-64.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Takeuchi F, Mcginnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, 2009; 5 (3): e1000433.</mixed-citation><mixed-citation xml:lang="en">Takeuchi F, Mcginnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, 2009; 5 (3): e1000433.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting, Blood, 2009; 113 (4): 784-92.</mixed-citation><mixed-citation xml:lang="en">Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting, Blood, 2009; 113 (4): 784-92.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study) J Am Coll Cardiol, 2010; 55 (25): 2804-12.</mixed-citation><mixed-citation xml:lang="en">Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study) J Am Coll Cardiol, 2010; 55 (25): 2804-12.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood, 2011; 118 (11): 3163-71.</mixed-citation><mixed-citation xml:lang="en">Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood, 2011; 118 (11): 3163-71.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 2007; 116 (22): 2563-70.</mixed-citation><mixed-citation xml:lang="en">Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 2007; 116 (22): 2563-70.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med, 2011; 13 (6): 509-18.</mixed-citation><mixed-citation xml:lang="en">Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med, 2011; 13 (6): 509-18.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation, 2012; 125 (16): 1997-2005.</mixed-citation><mixed-citation xml:lang="en">Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation, 2012; 125 (16): 1997-2005.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013; 369 (24): 2294-303.</mixed-citation><mixed-citation xml:lang="en">Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013; 369 (24): 2294-303.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kropacheva ES, Borovkov NN, Vavilova TV, et al. The rapid saturation of warfarin as a predictor of development of excessive anticoagulation. Modernization of the algorithm of selection of the dose of warfarin. Atherothrombosis 2015; 1: 75-86. Russian (Кропачева Е. С., Боровков Н. Н., Вавилова Т. В. и соавт. Быстрые темпы насыщения варфарином — предиктор развития чрезмерной гипокоагуляции. Модернизация алгоритма подбора дозы варфарина. Атеротромбоз 2015; 1: 75-86).</mixed-citation><mixed-citation xml:lang="en">Kropacheva ES, Borovkov NN, Vavilova TV, et al. The rapid saturation of warfarin as a predictor of development of excessive anticoagulation. Modernization of the algorithm of selection of the dose of warfarin. Atherothrombosis 2015; 1: 75-86. Russian (Кропачева Е. С., Боровков Н. Н., Вавилова Т. В. и соавт. Быстрые темпы насыщения варфарином — предиктор развития чрезмерной гипокоагуляции. Модернизация алгоритма подбора дозы варфарина. Атеротромбоз 2015; 1: 75-86).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2009; 361 (12): 1139-51.</mixed-citation><mixed-citation xml:lang="en">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2009; 361 (12): 1139-51.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2013; 2: e000067.</mixed-citation><mixed-citation xml:lang="en">Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2013; 2: e000067.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Khatib ML, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J, 2013; 34: 2464-71.</mixed-citation><mixed-citation xml:lang="en">Al-Khatib ML, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J, 2013; 34: 2464-71.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). Thromb Haemost, 2010, 8: 2182-91.</mixed-citation><mixed-citation xml:lang="en">Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). Thromb Haemost, 2010, 8: 2182-91.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Abumuaileq R R-Y, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace, 2015, 17 (5): 711-17.</mixed-citation><mixed-citation xml:lang="en">Abumuaileq R R-Y, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace, 2015, 17 (5): 711-17.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
